Intravenous ustekinumab maintenance treatment in patients with loss of response to subcutaneous dosing

BACKGROUND: Ustekinumab (UST) is indicated for the treatment of Crohn’s disease (CD) and Ulcerative Colitis (UC). Despite having shown clinical effectiveness in the real world, some patients may lose response over time or need a higher dose to achieve it. In this context, UST intravenous (IV) mainte...

Descripción completa

Detalles Bibliográficos
Autores principales: Argüelles-Arias, Federico, Valdés Delgado, Teresa, Maldonado Pérez, Belén, González Antuña, Jaime, Castro Laria, Luisa
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2023
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10467174/
https://www.ncbi.nlm.nih.gov/pubmed/37655058
http://dx.doi.org/10.1177/17562848231191670

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10467174/
https://www.ncbi.nlm.nih.gov/pubmed/37655058
http://dx.doi.org/10.1177/17562848231191670

Ejemplares similares